Clinical Trial Update: Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating dupilumab (Dupixent) for adults with refractory post-burn pruritus, currently recruiting at an ambulatory clinic.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-burn Pruritus
• Pruritus

Drugs mentioned

• DUPIXENT (DUPILUMAB)

Snippet

Sponsor: Akron Children's Hospital | Conditions: Pruritis | Phase 2 | Status: RECRUITING